Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Front Endocrinol (Lausanne). 2021 May 19;12:679000. doi: 10.3389/fendo.2021.679000. eCollection 2021.
Pancreatic neuroendocrine tumors (pNETs) are rare and part of the diverse family of neuroendocrine neoplasms (NENs). Somatostatin receptors (SSTRs), which are widely expressed in NENs, are G-protein coupled receptors that can be activated by somatostatins or its synthetic analogs. Therefore, SSTRs have been widely researched as a diagnostic marker and therapeutic target in pNETs. A large number of studies have demonstrated the clinical significance of SSTRs in pNETs. In this review, relevant literature has been appraised to summarize the most recent empirical evidence addressing the clinical significance of SSTRs in pNETs. Overall, these studies have shown that SSTRs have great value in the diagnosis, treatment, and prognostic prediction of pNETs; however, further research is still necessary.
胰腺神经内分泌肿瘤(pNET)较为罕见,属于神经内分泌肿瘤(NEN)大家族中的一员。生长抑素受体(SSTR)在 NEN 中广泛表达,属于 G 蛋白偶联受体,可被生长抑素或其合成类似物激活。因此,SSTR 已被广泛研究作为 pNET 的诊断标志物和治疗靶点。大量研究表明 SSTR 在 pNET 中具有重要的临床意义。本综述对相关文献进行了评估,以总结 SSTR 在 pNET 中的最新临床意义的实证证据。总体而言,这些研究表明 SSTR 在 pNET 的诊断、治疗和预后预测方面具有重要价值;然而,仍需要进一步的研究。